Core Viewpoint - ReShape Lifesciences Inc. will report its financial results for Q3 2024 on November 14, 2024, along with a corporate update [1] Group 1: Financial Results Announcement - The financial results for the third quarter ended September 30, 2024, will be reported after market on November 14, 2024 [1] - A conference call will be hosted on the same day at 4:30 pm ET, featuring Krishna K. Gupta, who will become Chairman of the combined company post-merger [2] Group 2: Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4] - The company’s FDA-approved Lap-Band System provides a minimally invasive long-term treatment for obesity, serving as an alternative to more invasive surgical options [4] - The investigational Diabetes Bloc-Stim Neuromodulation system utilizes proprietary technology for treating type 2 diabetes and metabolic disorders [4] - The Obalon balloon technology is a non-surgical, swallowable intra-gastric balloon designed for long-lasting weight loss [4]
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update